ReviewCurrent diabetes reports2022

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Hongyan Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.